- Home
- PHAR vs AVAH Comparison
PHAR vs AVAH Comparison
Compare PHAR & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- AVAH
- Stock Information
- Founded
- PHAR 1988
- AVAH 1984
- Country
- PHAR Netherlands
- AVAH United States
- Employees
- PHAR N/A
- AVAH N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- AVAH Hospital/Nursing Management
- Sector
- PHAR Health Care
- AVAH Health Care
- Exchange
- PHAR Nasdaq
- AVAH Nasdaq
- Market Cap
- PHAR 798.2M
- AVAH 872.6M
- IPO Year
- PHAR N/A
- AVAH 2021
- Fundamental
- Price
- PHAR $13.70
- AVAH $7.47
- Analyst Decision
- PHAR Strong Buy
- AVAH Buy
- Analyst Count
- PHAR 3
- AVAH 5
- Target Price
- PHAR $30.00
- AVAH $7.50
- AVG Volume (30 Days)
- PHAR 12.8K
- AVAH 1.8M
- Earning Date
- PHAR 07-31-2025
- AVAH 08-07-2025
- Dividend Yield
- PHAR N/A
- AVAH N/A
- EPS Growth
- PHAR N/A
- AVAH N/A
- EPS
- PHAR N/A
- AVAH 0.09
- Revenue
- PHAR $339,836,000.00
- AVAH $2,177,672,000.00
- Revenue This Year
- PHAR $12.88
- AVAH $9.80
- Revenue Next Year
- PHAR $8.54
- AVAH $4.77
- P/E Ratio
- PHAR N/A
- AVAH $78.74
- Revenue Growth
- PHAR 22.44
- AVAH 11.54
- 52 Week Low
- PHAR $6.73
- AVAH $3.67
- 52 Week High
- PHAR $17.08
- AVAH $7.66
- Technical
- Relative Strength Index (RSI)
- PHAR 67.43
- AVAH 77.99
- Support Level
- PHAR $12.13
- AVAH $7.03
- Resistance Level
- PHAR $12.76
- AVAH $7.61
- Average True Range (ATR)
- PHAR 0.89
- AVAH 0.47
- MACD
- PHAR 0.13
- AVAH 0.16
- Stochastic Oscillator
- PHAR 44.41
- AVAH 94.43
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About AVAH Aveanna Healthcare Holdings Inc.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.